0000950170-25-084609.txt : 20250610 0000950170-25-084609.hdr.sgml : 20250610 20250610213233 ACCESSION NUMBER: 0000950170-25-084609 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20250605 FILED AS OF DATE: 20250610 DATE AS OF CHANGE: 20250610 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Mazzacco Catherine CENTRAL INDEX KEY: 0001967722 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40587 FILM NUMBER: 251038667 MAIL ADDRESS: STREET 1: C/O KRYSTAL BIOTECH, INC. STREET 2: 2100 WHARTON STREET, SUITE 701 CITY: PITTSBURGH STATE: PA ZIP: 15203 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Sight Sciences, Inc. CENTRAL INDEX KEY: 0001531177 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 800625749 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4040 CAMPBELL AVE, STREET 2: SUITE 100 CITY: MENLO PARK STATE: CA ZIP: 94025 BUSINESS PHONE: (415) 889-0550 MAIL ADDRESS: STREET 1: 4040 CAMPBELL AVE, STREET 2: SUITE 100 CITY: MENLO PARK STATE: CA ZIP: 94025 4 1 ownership.xml 4 X0508 4 2025-06-05 0001531177 Sight Sciences, Inc. SGHT 0001967722 Mazzacco Catherine C/O SIGHT SCIENCES, INC. 4040 CAMPBELL AVE., SUITE 100 MENLO PARK CA 94025 true false false false false Common Stock 2025-06-05 4 A false 30952 0 A 78507 D Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person under the Issuer's Non-Employee Director Compensation Program. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The number of RSUs granted is equal to approximately $130,000 of shares of Common Stock as determined by the closing price on the grant date, June 5, 2025. The RSUs vest on the earlier of June 5, 2026 and the date of the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continued service as a director on the Company's board of directors through such vesting date. Includes (i) 37,492 shares of Common Stock, (ii) 30,952 RSUs which are subject to vesting as reported herein, and (iii) 10,063 RSUs granted to the Reporting Person on June 8, 2023 which are subject to vesting as previously reported. /s/ Jeremy Hayden, Attorney-in-Fact for Catherine Mazzacco 2025-06-10